Group 1 - The core point of the news is that southbound funds have reduced their holdings in Baize Medical (02609.HK) by 1.62% on October 27, 2025, amounting to a decrease of 106.2 million shares [1][2] - Over the past five trading days, southbound funds have reduced their holdings for four days, with a total net reduction of 257.4 million shares [1][2] - As of now, southbound funds hold 64.476 million shares of Baize Medical, representing 4.88% of the company's total issued ordinary shares [1][2] Group 2 - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Its business operations include hospital services, hospital management services, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2]

Core Insights - Southbound funds reduced their holdings in Baize Medical (02609.HK) by 1.7418 million shares on October 22, 2025, marking a decrease of 2.61% [1][2] - Over the past five trading days, there were four days of reductions, totaling a net decrease of 2.274 million shares [1] - In the last twenty trading days, southbound funds increased their holdings on twelve occasions, with a cumulative net increase of 45.6066 million shares [1] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Its business operations encompass hospital services, hospital management, supply of pharmaceuticals, medical devices, consumables, and other related services [2] - The company conducts cancer diagnosis, treatment, rehabilitation, and end-of-life care for patients, as well as early cancer screening, cancer vaccination, and health management services for other potential health populations [2] - Baize Medical primarily operates in the Chinese market [2]

Market Overview - The Hang Seng Index fell by 1.61%, down 415 points, closing at 25,472 points, while the Hang Seng Tech Index dropped by 2.81%. The early trading volume in the Hong Kong market was HKD 153.2 billion [1] Energy Sector - Gas stocks rose, with Zhongyu Energy (03633) increasing by over 10%. This surge is attributed to the early initiation of winter heating in Gansu and other regions due to continuous temperature drops, leading to increased natural gas demand [1] Biotechnology Sector - Newly listed stock Xuan Zhu Bio-B (02575) surged over 13%, reaching a new high, and is up more than 190% from its IPO price. Yimai Sunshine (02522) rose over 4% following the global launch of its medical imaging model product AIR. The performance of medical stocks varied, with Yaojie Ankang-B (02617.HK) up over 21%, Baize Medical (02609) up over 5%, while Kangfang Biotech (09926) fell by 2%. Kangning Jereh Pharma-B (09966) increased by over 13% after announcing a share buyback plan, with market attention on significant data from the ESMO conference [2] Precious Metals Sector - Laopu Gold (06181) rose over 4%, benefiting from increased channel expansion and upgrades, with institutions indicating that rising gold prices favor its high-end brand positioning [3] Hospitality Sector - Wanda Hotel Development (00169) increased by over 10% after completing a sale and announcing a special dividend of HKD 0.462 per share to be paid next month [4] Digital Assets Sector - Delin Holdings (01709) rose over 3% after entering a strategic cooperation agreement with Antalpha to promote business in the digital asset sector [5] Telecommunications Sector - Changfei Optical Fiber and Cable (06869) fell over 6%, having dropped 40% from its September peak due to declining fiber optic prices and shareholder sell-offs. Cryptocurrency-related stocks collectively declined, with Bitcoin experiencing significant volatility and a recent incident in the US stablecoin market. Mi Strategy (02440) fell by 4.36%, and OSL Group (00863) dropped by 3.99% [6] Semiconductor Sector - Chip stocks continued to decline, with SMIC (00981) down over 5% and Huahong (01347) down over 3%, as US export controls accelerate domestic semiconductor replacements [6]

Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 384,600 shares on October 15, 2025, marking a net increase of 2,892,600 shares over the last five trading days [1] - Over the past 20 trading days, Baize Medical has seen a total net increase of 67,140,600 shares from southbound funds, with 16 days of net buying activity [1] - As of now, southbound funds hold 67,140,600 shares of Baize Medical, representing 5.08% of the company's total issued ordinary shares [1] Trading Data Summary - On October 15, 2025, total shares held reached 67,140,600 with a change of 384,600 shares, reflecting a 0.58% increase [2] - On October 14, 2025, total shares held were 66,756,000 with a change of 180,000 shares, a 0.27% increase [2] - On October 13, 2025, total shares held were 66,576,000 with a change of 897,600 shares, a 1.37% increase [2] - On October 3, 2025, total shares held were 65,678,400 with a change of 1,597,200 shares, a 2.49% increase [2] - On October 2, 2025, total shares held were 64,081,200 with a change of -166,800 shares, a -0.26% decrease [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology [2] - The company offers comprehensive oncology medical services, including screening, diagnosis, treatment, and rehabilitation [2] - Key business areas include hospital operations, hospital management services, supply of pharmaceuticals, medical devices, and consumables [2] - Services provided encompass cancer diagnosis, treatment, rehabilitation, and end-of-life care, as well as early cancer screening, cancer vaccination, and health management for other potential health populations [2] - The company primarily operates in the Chinese market [2]

Group 1 - Mr. Fan Kunkun has submitted his resignation as the co-secretary of the company, effective from October 14, 2025 [1] - Following Mr. Fan's resignation, Mr. Yao Le has been appointed as the co-secretary, effective from October 14, 2025 [1] - Ms. Chen Shiting has submitted her resignation as (i) co-secretary; (ii) authorized representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) representative for receiving legal documents and notices in Hong Kong, effective from October 14, 2025 [1] Group 2 - After Ms. Chen's resignation, Ms. Fang Xilin has been appointed as co-secretary, authorized representative, and legal document agent, effective from October 14, 2025 [1] - Mr. Zhao Yongkai will continue to serve as another authorized representative [1]

Group 1 - Mr. Fan Kunkun has submitted his resignation as the co-secretary of the company, effective from October 14, 2025 [1] - Mr. Yao Le has been appointed as the co-secretary of the company, effective from October 14, 2025 [1] - Ms. Chen Shiting has submitted her resignation as (i) co-secretary; (ii) authorized representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) representative for receiving legal documents and notices in Hong Kong, effective from October 14, 2025 [1] - Ms. Fang Xilin has been appointed as co-secretary, authorized representative, and legal document agent, effective from October 14, 2025 [1] - Mr. Zhao Yongkai will continue to serve as another authorized representative [1]

Core Viewpoint - Baize Medical (02609.HK) announced the resignation of its co-secretary, Fan Kunkun, effective from October 14, 2025 [1] Group 1: Management Changes - Chen Shiting has submitted her resignation as (i) co-secretary; (ii) authorized representative under the Hong Kong Stock Exchange Listing Rules Section 3.05; and (iii) representative for receiving legal documents and notices in Hong Kong, effective from October 14, 2025 [1] - Fang Xilin has been appointed as co-secretary, authorized representative, and agent for legal documents, effective from October 14, 2025 [1] - Zhao Yongkai will continue to serve as another authorized representative [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任 何 損 失 承 擔 任 何 責 任。 Bayzed Health Group Inc 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） （股份代號：2609） 聯 席 公 司 秘 書、授 權 代 表 及 法 律 程 序 文 件 代 理 人 變 更； 及 豁免嚴格遵守上市規則第3.28條及第8.17條 聯 席 公 司 秘 書、授 權 代 表 及 法 律 程 序 文 件 代 理 人 變 更 佰 澤 醫 療 集 團（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事（「董 事」）會 （「董事會」）謹 此 宣 佈，范 坤 坤 先 生（「范先生」）已 提 呈 辭 任 本 公 司 聯 席 公 司 秘 書（「聯席公司秘書」），自2025年10月14日 起 生 效。 范 先 生 確 認 彼 與 董 事 會 並 無 意 見 分 歧，亦 無 有 關 彼 辭 任 之 事 宜 須 ...

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 佰澤醫療集團 （根據開曼群島法律註冊成立的有限公司） 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02609 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | | ...